We dont know what the long-term outcomes are going to be, so that is another big concern, Eichner adds
Choosing between oral and injectable BPC-157 isnt about convenience its about matching the delivery method to the goal
But we want all of our active pharmaceutical ingredients that come into this state to be of high quality, regardless of whether its a weight-loss drug or hormone-replacement therapy or anything else. Continuing innovation As Lilly prepares for the release of its own oral weight-loss drug, orforglipron, the company is looking to ensure it does not experience the same shortages it did in the early days of Mounjaro and Zepbound
Certificates are available on request and via the QR code on each vial label
Reviews of realworld data show that a significant portion of patients discontinue GLP1 therapy over time due to side effects, cost, or the burden of injections, which has driven interest in more convenient, needlefree delivery systems